SuperworthKiora Pharmaceuticals KPRX
- Market cap
- $10.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −85.0%
Kiora Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $16M | $20K | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | |
| R&D | $1.1M−19% | $1.1M+32% | $1.7M+284% | $2M+47% | $2.2M+101% | $1.9M+73% | $2.5M+50% | $2.6M+26% | $2.7M+25% | $2.9M+52% | $2.1M−16% | $2.1M−20% |
| SG&A | $1.4M−30% | $880.5K−68% | $1.3M+2% | $1.5M+40% | $1.4M−3% | $1.3M+51% | $1.5M+15% | $1.4M−12% | $1.4M+5% | $1.5M+10% | $1.6M+8% | $1.4M+2% |
| −$5.9M+60% | −$2.1M−20% | $13.2M | −$2.5M−3% | −$3.6M−39% | −$2.6M+21% | −$2.3M | −$2.4M−6% | −$794.4K−78% | −$7.3M+185% | −$2.5M+8% | −$2.2M−8% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | $13.5M | −$2.2M | −$3.4M | −$2.2M | −$2.1M | −$2.3M+2% | −$616.3K−82% | −$7.2M+232% | −$2.4M+17% | −$2.1M−8% |
| n/a | n/a | $0 | $0 | $0 | $2.1M | $123K | −$112.1K | −$643.1K | −$650K | $0 | $0 | |
| Net income | −$5.8M+13% | −$2.3M−9% | $13.5M | −$2.2M−15% | −$3.4M−41% | −$4.2M+86% | −$2.2M | −$2.2M−3% | $26.8K | −$6.5M+54% | −$2.4M+10% | −$2.1M−3% |
| −$7.30−87% | −$2.72−83% | $3.46 | −$0.53−93% | −$0.81−89% | −$1.00−63% | −$0.52 | −$0.54+2% | $0.01 | −$1.56+56% | −$0.58+12% | −$0.34−37% | |
| 789.7K+738% | 832.7K+430% | 3.9M+1780% | 4.2M+1041% | 4.2M+434% | 4.2M+406% | 4.2M+8% | 4M−4% | 4.4M+4% | 4.2M−1% | 4.2M−1% | 6.2M+55% |
Operating income: 3 periods, Q4 FY18 to Q4 FY20: not printed by the filing, worked out from its own lines.
EPS, diluted: 12 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Kiora Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals | $10.1M | n/m | 2.7× | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Kiora Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .